Strs Ohio acquired a new position in shares of Clovis Oncology in the 1st quarter valued at $896,000. During the trading on 09/19/2017, Company’s stock ranged from $184.62 to $189.85. Royce & Associates LP owned approximately 0.15% of Clovis Oncology worth $6,180,000 as of its most recent SEC filing.
Several hedge funds have recently made changes to their positions in CLVS. Wells Fargo & Company MN increased its holdings in Loxo Oncology by 33.3% during the 1st quarter. $70.50’s average target is -6.05% below currents $75.04 stock price. Gabelli Funds Ltd Company invested in 0% or 8,800 shares. Legato Capital Management LLC purchased a new stake in shares of Clovis Oncology in the 2nd quarter valued at $220,000. Manufacturers Life Insurance Com The has 0% invested in Loxo Oncology Inc (NASDAQ:LOXO) for 9,694 shares. About 1.20 million shares traded. It dived, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings. With 53,900 avg volume, 1 days are for CROSSROADS SYSTEMS INCORPORATED (OTCMKTS:CRDSQ)’s short sellers to cover CRDSQ’s short positions. Following the completion of the sale, the insider now directly owns 197,583 shares of the company’s stock, valued at $18,090,699.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The company has market cap of $3.19 million. The disclosure for this sale can be found here. Over the last three months, the shares of the company have changed -14.29% and performed 17.66% over the last six months. Corporate insiders own 27.80% of the company’s stock. About shares traded. Clovis Oncology Inc (NASDAQ:CLVS) has risen 282.71% since September 21, 2016 and is uptrending. (NASDAQ:CLVS) opened at 75.04 on Thursday. (NASDAQ:CLVS) previous 52-week high was $99.45 and moved up 145.91% over the same period, trading at a volume of 2.4 million. The stock closing price is now trading downward to its 50 day moving average with change of -3.17%, escalated to its 20 day moving average with figure of 4.66% and above its 200 day moving average with value 19.08%. (NASDAQ:CLVS) plummeted -0.95% to $76.01. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.15). The firm had revenue of $14.62 million for the quarter, compared to analysts’ expectations of $13.07 million. The business’s quarterly revenue was down 32.5% on a year-over-year basis. This indicates more upside for the $2.71B company.
In recent trading day Clovis Oncology, Inc.
ILLEGAL ACTIVITY NOTICE: “Clovis Oncology, Inc“. Jennison Associates Limited holds 450,247 shares. If you are accessing this story on another publication, it was copied illegally and republished in violation of US & global trademark & copyright legislation. The legal version of this piece can be read at https://www.equitiesfocus.com/2017/09/21/insider-selling-clovis-oncology-inc-clvs-insider-sells-208500-00-in-stock.html.
A number of equities research analysts have recently issued reports on CLVS shares. On June 23, 2017 Oppenheimer started covering the stock setting a rating of “Market Perform”. The mean rating score for this stock is at # ref.
In an analyst report sent to clients and investors this morning, Leerink Swann restate their Buy rating on Clovis Oncology (NASDAQ:CLVS) shares. The stock has “Buy” rating by Morgan Stanley on Monday, June 19. Equity research analysts have given opinions on where they foresees the stock level. The company presently has an average rating of “Buy” and a consensus target price of $84.91.
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. The Company’s product candidates include Rociletinib, Rubraca and Lucitanib. Its commercial product Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP), inhibitor of PARP1, PARP2 and PARP3 approved in the United States by the Food and Drug Administration (FDA), as monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the fix of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca.